AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint of overall survival with a hazard ratio of 0.908; stratified log-rank. No new safety signals were observed. Results from the Verona trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials will be informed by their treating physician. These data do not impact any current approved indications for venetoclax.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Growth: A Buy Rating Backed by Robust R&D and Strategic Advancements
- Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges
- AbbVie announces FDA approval for MAVYRET expanded indication
- AbbVie call volume above normal and directionally bullish
- AbbVie’s Promising Growth Trajectory: Strong Pipeline, Strategic Investments, and Global Expansion
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue